Moreover, thiazolidinediones (TZDs) such as rosiglitazone and pioglitazone, PPARγ agonists used for decades to treat type 2 diabetes due to its insulin sensitization activity (Saltiel and Olefsky, 1996; Malinowski and Bolesta, 2000; Hong et al., 2018) were recently repurposed to treat AD. The gene discussed is INS; the disease is Alzheimer disease.